Cargando…

Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing

Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion. Advances in sequencing technologies have since decreased costs to the point where it is now feasible to resequence a whole human genome for $1000 in a single day. These advances have allowed the generation of huge volumes...

Descripción completa

Detalles Bibliográficos
Autor principal: Field, Matt A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891608/
https://www.ncbi.nlm.nih.gov/pubmed/32623783
http://dx.doi.org/10.1111/imcb.12372
_version_ 1783652734376869888
author Field, Matt A
author_facet Field, Matt A
author_sort Field, Matt A
collection PubMed
description Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion. Advances in sequencing technologies have since decreased costs to the point where it is now feasible to resequence a whole human genome for $1000 in a single day. These advances have allowed the generation of huge volumes of high‐quality human sequence data used to construct increasingly large catalogs of both population‐level and disease‐causing variation. The existence of such databases, coupled with a high‐quality human reference genome, means we are able to interrogate and annotate all types of genetic variation and identify pathogenic variants for many diseases. Increasingly, sequencing‐based approaches are being used to elucidate the underlying genetic cause of autoimmune diseases, a group of roughly 80 polygenic diseases characterized by abnormal immune responses where healthy tissue is attacked. Although sequence data generation has become routine and affordable, significant challenges remain with no gold‐standard methodology to identify pathogenic variants currently available. This review examines the latest methodologies used to identify pathogenic variants in autoimmune diseases and considers available sequencing options and subsequent bioinformatic methodologies and strategies. The development of reliable and robust sequencing and analytic workflows to detect pathogenic variants is critical to realize the potential of precision medicine programs where patient variant information is used to inform clinical practice.
format Online
Article
Text
id pubmed-7891608
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78916082021-03-02 Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing Field, Matt A Immunol Cell Biol SPECIAL FEATURE: Omics in Immunology Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion. Advances in sequencing technologies have since decreased costs to the point where it is now feasible to resequence a whole human genome for $1000 in a single day. These advances have allowed the generation of huge volumes of high‐quality human sequence data used to construct increasingly large catalogs of both population‐level and disease‐causing variation. The existence of such databases, coupled with a high‐quality human reference genome, means we are able to interrogate and annotate all types of genetic variation and identify pathogenic variants for many diseases. Increasingly, sequencing‐based approaches are being used to elucidate the underlying genetic cause of autoimmune diseases, a group of roughly 80 polygenic diseases characterized by abnormal immune responses where healthy tissue is attacked. Although sequence data generation has become routine and affordable, significant challenges remain with no gold‐standard methodology to identify pathogenic variants currently available. This review examines the latest methodologies used to identify pathogenic variants in autoimmune diseases and considers available sequencing options and subsequent bioinformatic methodologies and strategies. The development of reliable and robust sequencing and analytic workflows to detect pathogenic variants is critical to realize the potential of precision medicine programs where patient variant information is used to inform clinical practice. John Wiley and Sons Inc. 2020-07-27 2021-02 /pmc/articles/PMC7891608/ /pubmed/32623783 http://dx.doi.org/10.1111/imcb.12372 Text en © 2020 The Authors. Immunology & Cell Biology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle SPECIAL FEATURE: Omics in Immunology
Field, Matt A
Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
title Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
title_full Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
title_fullStr Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
title_full_unstemmed Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
title_short Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
title_sort detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
topic SPECIAL FEATURE: Omics in Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891608/
https://www.ncbi.nlm.nih.gov/pubmed/32623783
http://dx.doi.org/10.1111/imcb.12372
work_keys_str_mv AT fieldmatta detectingpathogenicvariantsinautoimmunediseasesusinghighthroughputsequencing